tiprankstipranks
Trending News
More News >

Cyclopharm Limited Expands US Market Presence with Technegas™

Story Highlights
  • Cyclopharm Limited’s Technegas™ received USFDA approval, boosting US sales by 131% in 2024.
  • Key agreements with US healthcare providers expand Cyclopharm’s market reach and potential applications.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cyclopharm Limited Expands US Market Presence with Technegas™

Confident Investing Starts Here:

Cyclopharm Limited ( (AU:CYC) ) has issued an announcement.

Cyclopharm Limited has entered a new growth phase following the USFDA approval of Technegas™ for lung imaging, which has significantly boosted its sales in the United States. The company achieved a 131% increase in US sales in 2024, with continued momentum into 2025, and has secured key agreements with major healthcare providers, enhancing its market reach. The expansion into the US market is expected to accelerate research into new clinical applications, potentially unlocking a global market opportunity estimated at US$900 million. Additionally, Cyclopharm is strengthening its third-party distribution business, contributing to its revenue diversity and margin resilience.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited operates in the healthcare industry, specializing in medical imaging technology. Its primary product, Technegas™, is used for lung imaging and is particularly known for diagnosing Pulmonary Embolism (PE). The company is focused on expanding its market presence, especially in the United States, and is also involved in third-party distribution of radiopharmaceuticals and related equipment.

Average Trading Volume: 99,631

Technical Sentiment Signal: Sell

Current Market Cap: A$134.5M

Learn more about CYC stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1